|
The following is a review of diagnostic product developments worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Product developments in December 2006
Biomoda, Inc. signed an agreement to exclusively license cancer detection technology from Los Alamos National Laboratory. Biomoda's cancer detection technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells, which are non-invasively collected from lung sputum samples. The porphyrin then glows red under fluorescent light, easily identifying cancerous cells. This simple optical reading of a molecular cancer test is easily automated, permitting rapid, accurate, and inexpensive cancer screening of large populations. Diagnostic Hybrids and Immunicon Corporation signed a definitive license, development, supply and distribution agreement to develop and commercialize products for virus detection. The first product is a panel of multiplex respiratory virus and sexually transmitted infection assays. Instruments and kits developed under the agreement will be sold exclusively by DHI. The clinical virology product portfolio will be developed for Immunicon's EasyCount System. Ortho-Clinical Diagnostics received FDA clearance to market its Ortho T. cruzi Elisa Test System, a test to screen blood donors for T. cruzi, a blood-borne parasite that causes Chagas disease. In addition to screening donated whole blood, the test can screen plasma and serum samples from organ, cell and tissue donors. The test is not currently approved to diagnose the disease, the FDA said. Procter & Gamble Co. invested $325 million in a joint venture with Inverness Medical Innovations. The OTC medical devices will be made by Inverness and marketed and distributed by Procter & Gamble. The deal, expected to be finalized late in the first quarter of 2007, will not include diagnostics products in cardiology and diabetes. Response Biomedical Corporation entered into a worldwide, exclusive agreement with the medical division of the 3M Company for the development and commercialization of diagnostic products targeting hospital and community acquired infectious diseases using Response Biomedical's RAMP testing platform. As part of this collaboration, 3M is making an $8 million equity investment in Response Biomedical, representing approximately a 13% ownership position. Response Biomedical will be responsible for development and manufacturing of the RAMP-based products, while 3M will be responsible for clinical and regulatory matters, and all sales, marketing and distribution of the infectious disease tests. Spectral Diagnostics received FDA clearance to market its rapid test for West Nile Virus. Spectral plans to make the test available in the U.S. in time for the 2007 West Nile Virus season. Verax Biomedical signed a 10-year agreement with British Biocell International (BBI) to manufacture the Verax Platelet PGD Test. The agreement comes in anticipation of strong worldwide demand for the Platelet PGD Test and follows the recent Verax announcement of an exclusive worldwide distribution agreement with Abbott Diagnostics to market and distribute the test, which is currently being evaluated in clinical trials. The Platelet PGD Test is a rapid, disposable device designed to detect the presence of a broad range of bacterial contaminants in platelets just prior to transfusion.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@total.net with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: January 04, 2007 |
![[Page Banner Image]](images/hprods.gif){kind=small}
